How to Fight Insurance Denials for Pediatric Cancer Treatment: A Guide for Parents and Advocates

When your child is diagnosed with cancer, the treatment plan should be the only thing you're focused on—not insurance paperwork. Yet pediatric oncology denials are distressingly common. Insurers routinely deny coverage for Children's Oncology Group (COG) clinical trial enrollment, CAR-T cell therapy, proton beam radiation, out-of-state specialty center care, targeted therapies for rare mutations, and fertility preservation. These denials often cite "experimental" designations, network adequacy claims, or narrow readings of medical policy—even when the proposed treatment represents the frontline standard of care for your child's cancer. This guide walks you through the most common denial templates, the clinical evidence and policy citations that carry weight in appeals, and concrete steps to overturn each type of denial.

Why Insurers Deny Pediatric Oncology Treatment

1. "COG clinical trial enrollment is investigational / experimental"

Many pediatric cancers are so rare that COG trials are the standard of care. More than 60% of children with cancer enroll in COG trials, and these protocols define risk-adapted therapy for ALL, AML, neuroblastoma, Wilms tumor, and sarcomas. Yet insurers frequently deny coverage by labeling trial participation "investigational," ignoring the fact that COG trials provide the backbone chemotherapy, surgery, and radiation—not experimental drugs added on top.

2. "CAR-T is experimental / not medically necessary for this indication"

Kymriah (tisagenlecleucel) received FDA approval in August 2017 for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) in patients up to age 25. Despite this, insurers deny CAR-T as "experimental" or claim it's not appropriate for patients who haven't exhausted all other options—even when the patient has already failed two or more lines of chemotherapy and meets the FDA label and NCCN criteria precisely.

3. "Proton beam therapy is not superior to photon radiation / cost-prohibitive alternative"

Proton therapy reduces radiation dose to developing organs—critical for children with CNS tumors, head and neck cancers, orbital tumors, paraspinal lesions, and genitourinary malignancies. Insurers deny proton therapy citing lack of randomized controlled trials proving superiority, or pointing to higher costs. They ignore modeling studies, ASTRO model policy guidance, and the unique vulnerability of pediatric patients to late effects like growth impairment, neurocognitive decline, cardiac toxicity, and secondary malignancies.

4. "In-network facility can provide equivalent care / out-of-state center not medically necessary"

Many regions lack pediatric oncology subspecialty services. A community hospital with a general pediatric oncologist cannot deliver pediatric CAR-T (which requires REMS certification), perform tandem autologous stem cell transplant for neuroblastoma, administer proton therapy, or enroll patients in COG trials. Insurers nonetheless deny out-of-state single-case agreements, claiming network adequacy—even when the in-network facility openly acknowledges it lacks the required infrastructure.

5. "Fertility preservation / germline genetic testing is not covered / not medically necessary for this age"

Alkylating agents, pelvic radiation, and stem cell transplant conditioning can cause permanent infertility. ASCO and NCCN guidelines recommend discussing fertility preservation before treatment begins, and many state laws now mandate insurance coverage. Yet insurers deny sperm banking, oocyte cryopreservation, ovarian tissue freezing, and germline cancer-predisposition panel testing (Li-Fraumeni, NF1, DICER1, RB1), citing age restrictions, "elective" designations, or narrow policy language.

---

The Citations Insurers Respect

When you appeal, reference these specific guidelines, policies, and trials by name and year. Insurers dismiss vague appeals but take notice when you cite the sources their own medical directors rely on.

National Guidelines and Consensus Statements

• NCCN Guidelines: Pediatric Acute Lymphoblastic Leukemia, Pediatric Aggressive Mature B-Cell Lymphomas, Neuroblastoma, Wilms Tumor, Ewing Sarcoma, Osteosarcoma, etc. (updated annually). These guidelines endorse COG protocols as standard of care.
• NCCN Guidelines: Adolescent and Young Adult (AYA) Oncology (updated annually). Recognizes that AYA patients (ages 15–39) with ALL benefit from pediatric-style protocols and should be treated at centers with pediatric oncology expertise.
• ASCO/ASTRO Guidelines on Proton Beam Therapy (2017 and updates). Endorse proton therapy for pediatric CNS tumors, skull-base lesions, orbital tumors, and paraspinal sarcomas to reduce late effects.
• ASTRO Proton Therapy Model Policy (2017, updated 2020). Lists pediatric indications as appropriate uses of proton therapy, emphasizing reduction of integral dose and late toxicity in growing children.
• ASCO Fertility Preservation Guidelines (2018, updated 2023). Recommend discussing fertility preservation options before initiating gonadotoxic therapy for all post-pubertal and select prepubertal patients.
• NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic; Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric (cover germline testing for Li-Fraumeni, hereditary RB1, NF1, DICER1, and other pediatric cancer predisposition syndromes).

Pivotal Clinical Trials and Studies

• ELIANA trial (Kymriah CAR-T for r/r pediatric B-ALL) – Maude et al., NEJM 2018. Phase II trial showing 81% overall remission rate in heavily pretreated B-ALL patients up to age 21.
• ANBL0532 (high-risk neuroblastoma with dinutuximab maintenance) – Yu et al., NEJM 2010. Randomized trial demonstrating survival benefit of immunotherapy maintenance with dinutuximab (Unituxin).
• AALL0232 (COG high-risk B-ALL escalated methotrexate) – Larsen et al., JCO 2016. Backbone for current COG high-risk ALL protocols.
• AALL1731 – Current COG high-risk B-ALL protocol incorporating risk-adapted therapy based on MRD (minimal residual disease).
• SPRINT (proton vs. photon in medulloblastoma) – Yock et al., Lancet Oncology 2016. Showed significant reduction in acute toxicity and IQ preservation with proton therapy.
• COG AREN0532/0533 (Wilms tumor risk-adapted therapy) – Fernandez et al., JCO 2018. Defines current standard-of-care chemotherapy regimens by histology and stage.

FDA Approvals and Labels

• Kymriah (tisagenlecleucel) – FDA approval August 30, 2017, for r/r B-ALL age ≤25 years.
• Vitrakvi (larotrectinib) – FDA approval November 26, 2018, tumor-agnostic for NTRK fusion-positive solid tumors, including pediatric patients.
• Koselugo (selumetinib) – FDA approval April 10, 2020, for pediatric patients ≥2 years with NF1 and inoperable plexiform neurofibromas.
• Ojemda (tovorafenib) – FDA approval April 23, 2024, for pediatric patients ≥6 months with relapsed/refractory low-grade glioma (LGG) harboring BRAF alterations.
• Unituxin (dinutuximab) – FDA approval March 10, 2015, for high-risk neuroblastoma in combination with GM-CSF, IL-2, and isotretinoin.

---

How to Argue Against Each Major Denial Reason

1. Overturning "COG trial enrollment is investigational"

The core argument: COG trials provide the standard-of-care backbone therapy for pediatric cancers. The trial structure ensures uniform risk stratification, quality control, and real-time safety monitoring. Denying COG enrollment forces your child off the accepted standard.

Concrete steps:

• Get a letter from your pediatric oncologist stating:

- The COG protocol number (e.g., AALL1731) and the specific diagnosis, stage, and risk group.

- That the backbone chemotherapy agents, doses, and schedule in the trial match the NCCN-endorsed standard of care.

- That trial participation is the recommended treatment and refusal would result in substandard care or reliance on outdated regimens.

• Cite NCCN Pediatric ALL (or relevant tumor type) guidelines that reference COG protocols as Category 1 evidence (highest level).
• Cite your state's clinical trial coverage law if applicable. Many states require insurers to cover routine patient care costs in qualifying clinical trials. Federal employees and Medicare Advantage plans must cover under the Medicare National Coverage Determination for clinical trials.
• Reference the trial's NCT number on ClinicalTrials.gov to show it is an NCI-sponsored, phase III or standard-arm COG trial, not an early-phase experimental study.

Language for your appeal:

> "The Children's Oncology Group protocol AALL1731 is not an experimental add-on. It is the standard of care for high-risk B-ALL. NCCN Guidelines (Pediatric ALL, 2025) explicitly endorse COG protocols as the backbone therapy. Denying enrollment forces my child onto either an outdated regimen or no standardized protocol at all. Under [state clinical trial coverage law / Medicare NCD 310.1], routine care costs in qualifying clinical trials must be covered."

---

2. Overturning "CAR-T is experimental / not medically necessary"

The core argument: Kymriah is FDA-approved for r/r B-ALL up to age 25, and NCCN lists it as a preferred option after first or second relapse. Denying access ignores the FDA label and the ELIANA trial data showing 81% remission in patients who had exhausted standard chemotherapy.

Concrete steps:

• Confirm your child meets the FDA label: Relapsed or refractory B-cell precursor ALL, age ≤25 years, with two prior lines of therapy or relapse post-transplant.
• Get a letter from your oncologist documenting:

- Prior lines of therapy (e.g., frontline induction/consolidation, then salvage regimen such as blinatumomab or clofarabine).

- Current disease status (persistent MRD, morphologic relapse, extramedullary disease).

- Why additional chemotherapy or HSCT is not appropriate (e.g., chemo-refractory disease, lack of suitable donor, prior HSCT failure).

• Cite the ELIANA trial (Maude et al., NEJM 2018) and note the 81% overall remission rate and durable responses.
• Cite NCCN Guidelines: Pediatric ALL (current year), which list tisagenlecleucel as a Category 1 or 2A option for r/r B-ALL.
• Confirm the treating center is REMS-certified for Kymriah administration. Attach proof of certification if the insurer questions the facility's qualifications.

Language for your appeal:

> "Kymriah (tisagenlecleucel) received FDA approval in 2017 specifically for relapsed/refractory B-ALL in patients up to age 25. My child has failed [two lines of chemotherapy / prior HSCT] and meets the exact FDA indication. NCCN Pediatric ALL Guidelines (2025) list CAR-T as a preferred option in this setting. The ELIANA trial (Maude, NEJM 2018) demonstrated 81% remission in heavily pretreated patients. Denying FDA-approved therapy that matches the label and NCCN guidance is not evidence-based."

---

3. Overturning "Proton therapy is not superior / cost-prohibitive"

The core argument: In children, reducing integral radiation dose to normal tissues is paramount. Proton therapy's physical advantage (Bragg peak) spares developing brain, heart, lungs, and bone marrow. Insurers cannot demand randomized controlled trials that would be unethical to perform in children.

Concrete steps:

• Get a letter from your radiation oncologist explaining:

- The tumor location (e.g., medulloblastoma, ependymoma, craniopharyngioma, orbital rhabdomyosarcoma, paraspinal Ewing sarcoma).

- Specific organs at risk (OARs) that would receive significantly lower dose with protons (e.g., hippocampus, cochlea, heart, thyroid, ovaries).

- Predicted late effects with photon therapy vs. protons (e.g., IQ decline, hearing loss, growth hormone deficiency, secondary malignancy risk).

• Cite ASTRO Proton Therapy Model Policy (2020), which lists pediatric CNS tumors, skull-base tumors, orbital tumors, and paraspinal sarcomas as appropriate indications.
• Cite ASCO/ASTRO Guidelines (2017) endorsing proton therapy for select pediatric cases.
• Reference the SPRINT trial (Yock et al., Lancet Oncology 2016) showing reduced acute toxicity and IQ preservation in pediatric medulloblastoma.
• Include a dosimetric comparison plan if available—side-by-side IMRT vs. proton plans showing dose-volume histograms for critical structures.

Language for your appeal:

> "Proton beam therapy is not experimental for pediatric CNS tumors. The ASTRO Proton Therapy Model Policy (2020) explicitly lists children with CNS, skull-base, orbital, and paraspinal tumors as appropriate candidates. The SPRINT trial (Yock, Lancet Oncology 2016) demonstrated significant reduction in acute toxicity and cognitive preservation. A randomized trial comparing protons to photons in children would be unethical given the known physical dose advantage. The attached dosimetric comparison shows proton therapy will reduce dose to my child's [hippocampus/cochlea/heart] by [X Gy], directly lowering the risk of [neurocognitive decline/hearing loss/cardiac disease/secondary cancer]."

---

4. Overturning "In-network facility adequate / out-of-state center not medically necessary"

The core argument: Network adequacy is not satisfied if the in-network facility lacks the specialized infrastructure your child's treatment requires—COG trial access, pediatric CAR-T REMS certification, FACT-accredited pediatric BMT program, proton therapy, or pediatric surgical oncology subspecialty.

Concrete steps:

• Get a letter from your requested out-of-state COG center stating they can provide the required treatment and are credentialed/accredited (COG member institution, FACT-accredited BMT program, REMS-certified for CAR-T, proton-capable, etc.).
• Get a letter from the nearest in-network facility (or document in writing) explicitly stating they cannot provide the treatment because they lack [pediatric CAR-T certification / proton therapy / pediatric BMT program / enrollment in COG trial X / pediatric surgical oncology].
• Cite your insurance contract's network adequacy clause. Many policies require the insurer to cover out-of-network care at in-network cost-sharing when no in-network provider can deliver the medically necessary service.
• Cite state prompt-payment and network adequacy regulations that require access to subspecialty care within reasonable distance/time.
• Calculate travel burden. If the COG center is 200+ miles away but is the nearest facility with the required capability, document the distance, travel time, lodging costs, and family disruption.

Language for your appeal:

> "The nearest in-network facility is [Hospital Name], which has confirmed in writing it cannot provide [CAR-T / proton therapy / enrollment in COG trial AALL1731 / tandem autologous HSCT] because it lacks [REMS certification / proton therapy equipment / COG membership / FACT-accredited pediatric BMT program]. The requested out-of-state center, [Children's Hospital Name], is a COG member institution with [FACT accreditation / REMS certification / proton therapy] and can deliver the standard-of-care treatment. Under the plan's network adequacy provisions, out-of-network care must be covered at in-network rates when no in-network provider can furnish the medically necessary service."

---

5. Overturning "Fertility preservation not covered / not medically necessary"

The core argument: Alkylating agents, pelvic radiation, and transplant conditioning cause permanent gonadal damage. ASCO guidelines recommend discussing fertility preservation before starting gonadotoxic therapy. Many states have enacted laws requiring insurers to cover fertility preservation for iatrogenic infertility risk.

Concrete steps:

• Get a letter from your oncologist stating:

- The planned chemotherapy agents (e.g., cyclophosphamide, ifosfamide), cumulative alkylator dose, and/or radiation dose to gonads.

- The anticipated risk of permanent infertility (cite published gonadotoxicity tables or guidelines).

- That fertility preservation must occur before treatment initiation.

• Cite ASCO Fertility Preservation Guidelines (2023), which recommend offering fertility preservation to all patients at risk of infertility from cancer treatment.
• Cite your state's fertility preservation law if applicable (many states now require coverage for iatrogenic infertility, not just elective IVF).
• For germline testing, cite NCCN Genetic/Familial High-Risk Assessment Guidelines and note that identifying a cancer predisposition syndrome (Li-Fraumeni, hereditary RB1, DICER1) impacts surveillance, family planning, and eligibility for certain therapies.

Language for your appeal:

> "My child's treatment plan includes [cyclophosphamide 9 g/m² cumulative / total body irradiation conditioning for HSCT], which carries a high risk of permanent infertility. ASCO Fertility Preservation Guidelines (2023) recommend discussing and offering fertility preservation before initiating gonadotoxic therapy. [State law citation] requires coverage of fertility preservation for medically necessary cancer treatment. The requested [sperm banking / oocyte cryopreservation / ovarian tissue cryopreservation] must be performed before chemotherapy begins. Delaying or denying this coverage will result in irreversible loss of my child's future reproductive potential."

---

What We Do

We write insurance appeals for families fighting pediatric oncology denials. We translate COG protocols, NCCN and ASCO guidelines, pivotal trial data, ASTRO proton model policies, and FDA labels into structured, citation-heavy appeal letters and external review submissions. We help you gather the right supporting letters from your oncology team, compile dosimetric comparisons for radiation denials, and meet tight appeal deadlines. If you've received a denial for CAR-T, proton therapy, out-of-state COG center care, fertility preservation, or any other pediatric cancer treatment, we can help you build the case to overturn it.

---

Sources

1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-448.

2. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. N Engl J Med. 2010;363(14):1324-1334.

3. Larsen EC, Devidas M, Chen S, et al. Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. J Clin Oncol. 2016;34(20):2380-2388.

4. Yock TI, Yeap BY, Ebb DH, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. Lancet Oncol. 2016;17(3):287-298.

5. Fernandez CV, Mullen EA, Chi YY, et al. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532. J Clin Oncol. 2018;36(3):254-261.

6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pediatric Acute Lymphoblastic Leukemia. Version 1.2025.

7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Adolescent and Young Adult (AYA) Oncology. Version 2.2024.

8. Loren AW, Mangu PB, Beck LN, et al. Fertility Preservation for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2013;31(19):2500-2510. Updated 2018, 2023.

9. Hahn CA, Yock TI. American Society for Radiation Oncology (ASTRO) Proton Beam Therapy Task Force. Proton Beam Therapy Model Policy. 2017, updated 2020.

10. U.S. Food and Drug Administration. Kymriah (tisagenlecleucel) approval letter. August 30, 2017.

11. U.S. Food and Drug Administration. Vitrakvi (larotrectinib) approval letter. November 26, 2018.

12. U.S. Food and Drug Administration. Koselugo (selumetinib) approval letter. April 10, 2020.

13. U.S. Food and Drug Administration. Ojemda (tovorafenib) approval letter. April 23, 2024.

14. U.S. Food and Drug Administration. Unituxin (dinutuximab) approval letter. March 10, 2015.

15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2025.